Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4
Dianhua Jiang, … , Andrew D. Luster, Paul W. Noble
Dianhua Jiang, … , Andrew D. Luster, Paul W. Noble
Published May 17, 2010
Citation Information: J Clin Invest. 2010;120(6):2049-2057. https://doi.org/10.1172/JCI38644.
View: Text | PDF
Research Article Pulmonology Article has an altmetric score of 11

Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4

  • Text
  • PDF
Abstract

Pulmonary fibrosis is a progressive, dysregulated response to injury culminating in compromised lung function due to excess extracellular matrix production. The heparan sulfate proteoglycan syndecan-4 is important in mediating fibroblast-matrix interactions, but its role in pulmonary fibrosis has not been explored. To investigate this issue, we used intratracheal instillation of bleomycin as a model of acute lung injury and fibrosis. We found that bleomycin treatment increased syndecan-4 expression. Moreover, we observed a marked decrease in neutrophil recruitment and an increase in both myofibroblast recruitment and interstitial fibrosis in bleomycin-treated syndecan-4–null (Sdc4–/–) mice. Subsequently, we identified a direct interaction between CXCL10, an antifibrotic chemokine, and syndecan-4 that inhibited primary lung fibroblast migration during fibrosis; mutation of the heparin-binding domain, but not the CXCR3 domain, of CXCL10 diminished this effect. Similarly, migration of fibroblasts from patients with pulmonary fibrosis was inhibited in the presence of CXCL10 protein defective in CXCR3 binding. Furthermore, administration of recombinant CXCL10 protein inhibited fibrosis in WT mice, but not in Sdc4–/– mice. Collectively, these data suggest that the direct interaction of syndecan-4 and CXCL10 in the lung interstitial compartment serves to inhibit fibroblast recruitment and subsequent fibrosis. Thus, administration of CXCL10 protein defective in CXCR3 binding may represent a novel therapy for pulmonary fibrosis.

Authors

Dianhua Jiang, Jiurong Liang, Gabriele S. Campanella, Rishu Guo, Shuang Yu, Ting Xie, Ningshan Liu, Yoosun Jung, Robert Homer, Eric B. Meltzer, Yuejuan Li, Andrew M. Tager, Paul F. Goetinck, Andrew D. Luster, Paul W. Noble

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Total
Citations: 2 6 5 6 7 9 4 9 4 8 4 6 6 12 13 101
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2015 (4)

Title and authors Publication Year
Syndecan 4 mediates Nrf2-dependent expansion of bronchiolar progenitors that protect against lung inflammation
A Santoso, T Kikuchi, N Tode, T Hirano, R Komatsu, T Damayanti, H Motohashi, M Yamamoto, T Kojima, T Uede, T Nukiwa, M Ichinose
Molecular Therapy 2015
The myofibroblast, a key cell in normal and pathological tissue repair
IA Darby, N Zakuan, F Billet, A Desmoulière
Cellular and Molecular Life Sciences 2015
CXCR3 Requirement for the Interleukin-13–Mediated Up-Regulation of Interleukin-13Rα2 in Pulmonary Fibroblasts
JC Barnes, RV Lumsden, J Worrell, IP Counihan, SL O’Beirne, JA Belperio, A Fabre, SC Donnelly, D Boylan, R Kane, MP Keane
American journal of respiratory cell and molecular biology 2015
Methylation-mediated BMPER expression in fibroblast activation in vitro and lung fibrosis in mice in vivo
C Huan, T Yang, J Liang, T Xie, L Cheng, N Liu, A Kurkciyan, JM Mena, C Wang, H Dai, PW Noble, D Jiang
Scientific Reports 2015

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Referenced in 6 patents
Highlighted by 1 platforms
93 readers on Mendeley
See more details